文献速递胸部肿瘤

复合性小细胞肺癌:是否为一个独立实体?

Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?
PubMed 文献 · J Thorac Oncol · 2017-10-31

该研究回顾性分析了2005至2015年间205例手术切除的小细胞肺癌(SCLC)病例,其中10例为复合性小细胞肺癌(CSCLC)。CSCLC与纯SCLC在临床特征上无显著差异,但CSCLC的中位生存期显著缩短(26个月 vs 58个月,p=0.030)。对3例CSCLC进行显微切割和靶向外显子测序发现,约75%的体细胞突变存在于两种成分中,但也存在各成分独有的突变和扩增。

要点

  • CSCLC与纯SCLC临床病理特征无显著差异。
  • CSCLC患者的总生存期较纯SCLC显著缩短。
  • CSCLC不同组织学成分间遗传高度一致但存在差异。

核心结论

  • CSCLC与纯SCLC在临床和病理上无显著差异,但CSCLC与更差的总生存相关。
  • CSCLC的组织学成分间遗传高度一致,但也存在 divergent 基因型,提示共同前体细胞后续获得致癌改变。

研究设计与样本

  • 回顾性分析2005年至2015年间手术切除的205例SCLC病例,其中170例有足够组织学材料。
  • 所有CSCLC病例经组织学检查和免疫组化确认。
  • 对3例CSCLC的不同成分进行显微切割和靶向外显子测序。

主要发现

  • 在170例有足够组织学材料的病例中,鉴定出10例CSCLC,其中5例第二成分为鳞状细胞癌。
  • CSCLC与纯SCLC在临床特征上无显著差异。
  • 中位随访时间为36个月,纯SCLC和CSCLC的中位生存时间分别为58个月和26个月(p=0.030)。
  • 3例CSCLC的不同成分测序显示,约75%的体细胞突变存在于两种成分中。
  • 存在15个基因突变或6个扩增仅见于其中一种成分。

临床怎么用

  • CSCLC患者预后较纯SCLC差,需更密切随访。
  • CSCLC不同成分间遗传高度一致,提示治疗可能针对共同驱动事件。

局限性

  • 仅3例CSCLC进行了显微切割和测序,样本量小。
  • 回顾性研究,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SCLC accounts for 15% and 20% of all lung cancers, with combined SCLC (CSCLC) comprising 2% to 5%. Little is known about the clinical characteristics and molecular changes associated with the various histologic components. METHODS: A total of 205 SCLC cases were resected between 2005 and 2015. Clinical and pathologic features were analyzed. All CSCLC cases were confirmed by histologic examination and immunohistochemistry. The individual components were microdissected using a novel automated dissection system, and DNA was extracted and subjected to targeted exome sequencing. RESULTS: A total of 10 cases of CSCLC were identified out of 170 cases with adequate histologic material; squamous cell carcinoma comprised the second component in half of these (n = 5). There were no significant differences between CSCLC and pure SCLC with respect to clinical features. The median follow-up time was 36 months. The median survival times of patients with pure SCLC and CSCLC were 58 months and 26 months, respectively (p = 0.030). The different components of three cases of CSCLC were deemed adequate for microdissection and sequencing. Approximately 75% of the identified somatic mutations were present in both components. There were also 15 gene mutations or six amplifications unique to only one of the components. CONCLUSIONS: We identified no significant clinical or pathologic differences between pure SCLC and CSCLC; CSCLC was associated with decreased overall survival compared with pure SCLC. The histologic components of CSCLC had high genetic concordance but also showed divergent genotypes. These findings may suggest a common precursor with subsequent acquisition of oncogenic changes in CSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao X, McCutcheon JN, Kallakury B, et al. Combined Small Cell Carcinoma of the Lung: Is It a Single Entity? J Thorac Oncol. 2017. PMID: 29101056. doi:10.1016/j.jtho.2017.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。